ImmuCell Corporation
ICCC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.74 | -0.48 | 0.04 | -0.13 |
| FCF Yield | 0.00% | 2.30% | 2.89% | -0.43% |
| EV / EBITDA | 93,864.88 | 54.85 | 23.67 | 33.69 |
| Quality | ||||
| ROIC | 0.00% | 1.29% | 2.56% | 1.44% |
| Gross Margin | 42.92% | 43.72% | 41.58% | 36.54% |
| Cash Conversion Ratio | 3.19 | 1.09 | -0.01 | 0.91 |
| Growth | ||||
| Revenue 3-Year CAGR | 19.47% | 21.70% | 19.46% | 12.58% |
| Free Cash Flow Growth | 0.00% | 16.19% | 724.68% | 72.62% |
| Safety | ||||
| Net Debt / EBITDA | 91,038.00 | 6.37 | 4.49 | 6.66 |
| Interest Coverage | 0.00 | 4.56 | 8.74 | 4.96 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.44 | 640.61 | 0.69 |
| Cash Conversion Cycle | 322,440.73 | 207.28 | 0.16 | 157.13 |